Willow Liu | Pharmacology | Best Researcher Award

Dr.Willow Liu | Pharmacology | Best Researcher Award 

PhD at American Association of Chinese herbs, United States

Dr. Willow Liu, a distinguished scientist 🧪🔬, holds a Ph.D. in Natural Product Chemistry from Shenyang Pharmaceutical University, China (1994). She further honed her expertise as an Alexander von Humboldt Research Fellow at Düsseldorf University, Germany (1996-1997), and as a Post-doctoral Research Scientist at Columbia University, USA (1998-1999) under Prof. Rudolf Bauer and Prof. Koji Nakanishi, respectively. With a rich educational background and international training, Dr. Liu has made significant contributions to the field of natural product chemistry, leaving an indelible mark on scientific research. 🌐

Publication Profile :

Scopus 

Education & Training :

Dr. Willow Liu, an accomplished scientist 🧪🔬, boasts a diverse educational journey. She earned her Ph.D. in Natural Product Chemistry under the guidance of Prof. XinSheng Yao at Shenyang Pharmaceutical University, China (1994). Subsequently, she expanded her knowledge as an Alexander von Humboldt Research Fellow at Düsseldorf University, Germany (1996-1997), and as a Post-doctoral Research Scientist in Prof. Koji Nakanishi’s group at Columbia University, USA (1998-1999). Dr. Liu’s academic prowess extends to a Master’s in Medicine from Liaoning College of Traditional Chinese Medicine, China (1991), and a Bachelor’s in Chinese Material Medica from Liaoning College of Traditional Chinese Pharmacology, China (1985). 🎓

License & Certificate :

Dr. Willow Liu holds prestigious certifications in Oriental Medicine, Acupuncture, and Chinese Herbology, exemplifying her commitment to holistic healthcare. Since 2006, she has been a Diplomate in Oriental Medicine, Acupuncture, and Chinese Herbology, accredited by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM). Additionally, she is a Licensed Acupuncturist in California, bringing her expertise to the forefront of alternative medicine. Dr. Liu’s dedication to these practices reflects a deep understanding of traditional healing methodologies, making her a trusted practitioner in the field. 🌿🎓

Working Experience :

Dr. Willow Liu, a seasoned professional in holistic healthcare 🌿, has amassed a wealth of experience across diverse roles. Currently serving as the Founder and Director of the TCM Health Education & Research Center (non-profit), she focuses on education and clinical studies related to acupuncture and Chinese herbs. Dr. Liu has held leadership positions as the Founder and CEO of TAT Health Group LLC, Expert Pharmaceutical LLC, and Best Lab LLC, contributing to dietary supplements, manufacturing, and testing labs. With a passion for patient care, she is the Founder, Owner, and Practitioner of 21st Century Herbs & Health Inc. Additionally, Dr. Liu has shared her knowledge as a part-time Professor and Teaching Faculty at various institutions, highlighting her commitment to education and research. 🎓🌐

Honors & Awards :

Dr. Willow Liu’s illustrious career is adorned with accolades and leadership roles, showcasing her expertise and impact in the field of Chinese medicine. Currently, she serves as a Peer Reviewer for the Chinese Journal of Integrative Medicine and Evidence-Based Complementary and Alternative Medicine (eCAM). As the Executive Director of the World Federation of Chinese Medicine Societies (WFCMS) – Specialty Committee of Natural Therapy since 2011, she contributes to advancing global awareness of natural therapies. Dr. Liu’s achievements include being interviewed by China Central Television International Channel (CCTV4) and receiving awards such as the Outstanding Young Scientist and the Kobayashi Award. Her dedication and leadership have left an indelible mark on the realm of traditional Chinese medicine. 🏆🌐

Research Focus :

Dr. Willow Liu, a distinguished researcher 🌐🔍, focuses on the intersection of traditional Chinese medicine and modern pharmacology. Her extensive work spans various areas, from herbal medicine and acupuncture to the development of dietary supplements. With a strong emphasis on clinical practice, she has contributed significantly to the understanding of Chinese materia medica. As an editor of “Traditional Herbal Medicine Research Methods,” she emphasizes identification, analysis, bioassay, and pharmacological studies. Dr. Liu’s publications range from monographs on herbal drugs to articles addressing teratogenicity research and the importance of clinical practice in Chinese herbal formula studies. 📚💊

Publication Top Notes :

  1. Traditional Herbal Medicine Research Methods 
  2. What has been overlooked on the study of Chinese materia medica in the West?
  3. Traditional herbal medicine research methods : identification, analysis, bioassay, and pharmaceutical and clinical studies
  4. Bioassays for Screening and Functional Elucidation of Herbal Medicines
  5. Introduction to Traditional Herbal Medicines and their Study
  6. Understanding Traditional Chinese Medicine and Chinese Herbs

Walaa Abdel Wahab | Microbial enzymes | Best Researcher Award

Assist Prof Dr.Walaa AbdelWahab : Microbial enzymes | Best Researcher Award

Ph.D. at National Research Centre, Egypt

🔬 Dr. Walaa Abdel Wahab, an accomplished microbiologist, earned her Ph.D. in Microbiology from Ain Shams University in 2014, specializing in microbial chitinases. Prior to this, she obtained her Master’s degree from Al-Azhar University in 2010, focusing on keratinase studies from marine bacteria. Currently serving as an Assistant Professor in the Chemistry of Natural and Microbial Products Department at the National Research Center since March 2020, Dr. Wahab contributes significantly to pharmaceutical and drug industries research. Her dedication to advancing microbiological knowledge underscores her commitment to scientific exploration and innovation. 🌐

Publication Profile :

Schopus profile

Orcid Profile

Education :

🔬 Dr. Walaa Abdel Wahab, a distinguished microbiologist, holds a Ph.D. in Microbiology from Ain Shams University (2014), specializing in “Studies on Microbial Chitinases.” She earned her Master’s degree in Microbiology from Al-Azhar University in 2010, conducting groundbreaking research on the “Microbiological and Biochemical Studies on Keratinase of Bacteria Isolated from the Marine Environment.” Achieving academic excellence, she completed her Bachelor’s degree in Microbiology at Al-Azhar University in 2004 with honors. Currently an Assistant Professor at the National Research Center, her research contributions have significantly impacted the field, showcasing a lifelong dedication to advancing microbiological understanding. 🌐

Career :

👩‍🔬 Dr. Walaa Abdel Wahab, currently serving as an Assistant Professor in the Chemistry of Natural and Microbial Products Department at the National Research Center since March 31, 2020, brings a wealth of expertise to the field. Prior to her professorial role, she held the position of Researcher in the Pharmaceutical and Drug Industries Research Division from February 2, 2015, to March 31, 2020. Her academic journey began as a Researcher Assistant in the same department from July 26, 2010, to February 2, 2015. Dr. Wahab’s early dedication to scientific inquiry is evident during her scholarship at the Chemistry of Natural and Microbial Products Department, sponsored by the Scientific Search Academy from March 5, 2006, to July 26, 2010. 🌱

Research Focus :

🔬 Dr. Walaa Abdel Wahab is a dedicated researcher with a multifaceted focus on microbiology, showcased in her prolific contributions across various scientific journals. Her research spans diverse areas, including the production of low-lactose yogurt using β-galactosidase, statistical optimization of milk clotting enzyme production, and the characterization of enzymes from microbial isolates. Dr. Wahab explores eco-friendly substrates, such as rice straw and orange peel, for enzyme production and delves into the immobilization and application of enzymes for therapeutic and industrial purposes. With expertise in enzymology and microbial pathogenesis, her work significantly advances knowledge in these fields. 🌐🧪

Publication Top Notes :

Philippe Collery | Recherche Thérapeutique | Excellence in Research

Dr. Philippe Collery: Recherche Thérapeutique

👨‍⚕️ Dr. Philippe Collery is a distinguished figure in the medical field, embarking on his journey in 1967 as an Intern at the Universitary Hospital of Reims, where he honed his skills until 1978. Over the years, he earned his stripes, becoming a Medical Doctor in 1976, a Specialist in Internal Medicine in 1980, and an Oncologist in 1987. His dedication continued as a Medical Assistant from 1978 to 1982 and later as a Medical Physician at the Universitary Hospital of Reims from 1982 to 2000.

From 2000 to 2013, Dr. Collery served as an Oncologist at the Polyclinique Maymard in Corsica, France, contributing significantly to cancer care. Currently, he wears the hat of the Manager at the Society for Coordination for Therapeutic Researches since 2005, spearheading breakthroughs in pharmaceuticals. Notably, he is the owner of the patent on “Rhenium complexes and their pharmaceutical use,” securing European and US patents in 2015, followed by Japanese and Canadian patents in 2017.

Dr. Collery’s influence extends beyond clinical practice; he organized the 1st International Symposium on Metal Ions in Biology and Medicine in Reims in 1990, garnering official sponsorship from the Food and Drug Administration (FDA). As a co-editor of 11 proceeding books on Metal Ions in Biology and Medicine and an author of over 100 research articles, he remains at the forefront of scientific discourse. Dr. Collery is a member of the International Scientific Committee for various Anticancer Research conferences, actively contributing to the field. His role as a coordinator for clinical trials on gallium chloride underscores his commitment to advancing oncological research. 🌐🔬👨‍⚕️

Professional Profiles:

Scopus

Orcid

Publication Top Note:
  • Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice
    • Author: Collery, P., Michalke, B., Lucio, M., … Schmid-Antomarchi, H., Schmid-Alliana, A.
    • Year: 2023
    • Journal: Anticancer Research
    • Volume: 43(3)
    • Pages: 1017–1023
    • Citations: 1 📚🔬
  • Remarkable Effects of a Rhenium(I)-diselenoether Drug on the Production of Cathepsins B and S by Macrophages and their Polarizations
    • Author: Collery, P., Desmaële, D., Harikrishnan, A., Veena, V.
    • Year: 2023
    • Journal: Current Pharmaceutical Design
    • Volume: 29(30)
    • Pages: 2396–2407
    • Citations: 0 📚⚛️
  • Quantification of drug loading in polymeric nanoparticles using AFM-IR technique: a novel method to map and evaluate drug distribution in drug nanocarriers
    • Author: Ural, M.S., Dartois, E., Mathurin, J., … Deniset-Besseau, A., Gref, R.
    • Year: 2022
    • Journal: Analyst
    • Volume: 147(23)
    • Pages: 5564–5578
    • Citations: 2 📚🔬
  • Relationship between the oxidative status and the tumor growth in transplanted triple-negative 4T1 breast tumor mice after oral administration of rhenium(I)-diselenoether
    • Author: Collery, P., Lagadec, P., Krossa, I., … Schmid-Antomarchi, H., Schmid-Alliana, A.
    • Year: 2022
    • Journal: Journal of Trace Elements in Medicine and Biology
    • Volume: 71
    • Pages: 126931
    • Citations: 3 📚🧪
  • Effects of rhenium(I)-diselenoether and of its diselenide ligand on the production of cathepsins B and S by MDA-MB231 breast malignant cells
    • Author: Collery, P., Veena, V., Desmaële, D., Harikrishnan, A., Lakshmi, B.
    • Year: 2021
    • Journal: Anticancer Research
    • Volume: 41(12)
    • Pages: 5997–6001
    • Citations: 4 📚⚛️
  • A new model applied for evaluating a rhenium-diselenium drug: Breast cancer cells stimulated by cytokines induced from polynuclear cells by LPS
    • Author: Veena, V., Harikrishnan, A., Lakshmi, B., … Desmaele, D., Collery, P.
    • Year: 2020
    • Journal: Anticancer Research
    • Volume: 40(4)
    • Pages: 1915–1920
    • Citations: 11 📚🧬
  • The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers
    • Author: Collery, P., Veena, V., Harikrishnan, A., Desmaele, D.
    • Year: 2019
    • Journal: Investigational New Drugs
    • Volume: 37(5)
    • Pages: 973–983
    • Citations: 31 📚⚛️
  • Design of rhenium compounds in targeted anticancer therapeutics
    • Author: Collery, P., Desmaele, D., Vijaykumar, V.
    • Year: 2019
    • Journal: Current Pharmaceutical Design
    • Volume: 25(31)
    • Pages: 3306–3322
    • Citations: 45 📚⚛️
  • Strategies for the development of selenium-based anticancer drugs
    • Author: Collery, P.
    • Year: 2018
    • Journal: Journal of Trace Elements in Medicine and Biology
    • Volume: 50
    • Pages: 498–507
    • Citations: 67 📚🔍